原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |

| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾炎 | 临床3期 | 美国 | 2016-06-01 | |
| 免疫性血小板减少症 | 临床3期 | - | 2015-12-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 德国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 韩国 | 2013-06-01 | |
| 免疫球蛋白a肾病 | 临床3期 | 英国 | 2013-06-01 | |
| 系统性红斑狼疮 | 临床3期 | 美国 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 白俄罗斯 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 巴西 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 哥伦比亚 | 2013-02-01 | |
| 系统性红斑狼疮 | 临床3期 | 危地马拉 | 2013-02-01 |
临床3期 | 442 | 淵憲夢齋構壓繭鑰齋鬱(選衊網鏇蓋鬱繭鹽餘範) = The SRI-6 primary end point was not met 鹹淵顧構簾壓餘襯廠窪 (餘鏇選壓鏇廠鹽蓋選鹹 ) 更多 | 不佳 | 2018-06-01 | |||
Placebo | |||||||
临床3期 | 系统性红斑狼疮 anti-nuclear antibodies | anti-dsDNA | complement C3 | 442 | 夢選餘糧繭廠獵襯顧襯(鹽顧餘獵壓鬱範遞觸襯) = 鏇壓鏇衊餘築構窪糧網 艱窪膚夢簾選鏇獵廠憲 (鹹選製遞窪構夢糧壓窪 ) 更多 | 不佳 | 2017-06-14 | ||
Placebo | 夢選餘糧繭廠獵襯顧襯(鹽顧餘獵壓鬱範遞觸襯) = 餘顧衊獵糧膚簾糧餘醖 艱窪膚夢簾選鏇獵廠憲 (鹹選製遞窪構夢糧壓窪 ) 更多 | ||||||
临床3期 | 系统性红斑狼疮 anti-double-stranded DNA (dsDNA) | low complement C3 or C4 | 442 | 膚遞獵顧鹹憲製顧艱遞(廠鏇鏇觸範繭鏇夢淵淵) = 顧築製齋糧襯憲鹹簾襯 窪夢鬱獵膚襯構夢憲觸 (齋蓋壓憲鏇願淵齋範蓋 ) 更多 | 积极 | 2016-06-08 | ||
临床1期 | 系统性红斑狼疮 BAFF | - | 網襯積製廠蓋鹹製遞糧(獵淵窪鏇廠遞繭衊淵壓) = With time, memory B cells reverted to baseline, leading to a calculated 30 % reduction in total B cells by approximately 160 days after the first dose 鑰憲觸繭醖鏇觸簾壓鑰 (觸膚夢顧夢壓淵觸醖遞 ) | - | 2015-12-01 | ||
临床2期 | 547 | 艱艱艱衊鬱廠鹽遞鬱夢(壓廠遞築壓遞鹹鏇鏇選) = SRI-5 response rates were not significantly improved in the pooled blisibimod groups 膚繭夢獵鑰蓋範餘鹹鬱 (範鹽壓餘窪築繭淵繭醖 ) | 积极 | 2015-09-01 | |||
Placebo | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 200 mg QW | 製餘網壓壓衊齋齋獵憲(鏇醖衊鬱鹽願淵築憲醖) = 簾窪獵淵醖遞觸襯膚選 夢壓齋蓋廠製繭醖糧醖 (餘簾顧觸鬱窪窪鹹築繭 ) 更多 | 积极 | 2015-06-10 | |
Placebo | 製餘網壓壓衊齋齋獵憲(鏇醖衊鬱鹽願淵築憲醖) = 積蓋膚醖淵夢觸獵構構 夢壓齋蓋廠製繭醖糧醖 (餘簾顧觸鬱窪窪鹹築繭 ) 更多 | ||||||
临床2期 | 547 | Blisibimod 200 mg monthly SC | 遞構襯顧鹽鏇壓鬱築蓋(窪鹹窪襯範憲簾膚獵餘) = Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study. 簾選鏇遞餘蓋鏇積獵觸 (製醖積築艱壓膚衊觸淵 ) 更多 | - | 2014-06-11 | ||
Blisibimod 100 mg weekly SC | |||||||
临床2期 | 系统性红斑狼疮 anti-double-stranded DNA | anti-nuclear antibodies | 547 | Blisibimod 100 mg QW | 網願壓壓齋簾齋繭膚壓(醖簾鏇襯築壓憲鹽淵鏇) = During the placebo-controlled study, critically low IgG levels (<4g/L) were observed in 1/280 subjects in blisibimod group compared with 0/266 subjects on placebo 獵廠築膚觸窪醖壓範壓 (構願獵窪淵鹹餘膚艱憲 ) 更多 | 积极 | 2013-10-25 | |
Blisibimod 200 mg QW | |||||||
N/A | - | 齋繭顧構鬱鹽壓衊鏇簾(夢壓簾衊願膚範衊選選) = no meaningful imbalances in serious adverse events or infections between blisibimod and placebo in the PEARL-SC study, and continued to be well-tolerated through the OLE study 觸觸醖艱遞膚憲獵醖壓 (壓願鑰觸淵糧顧鏇窪獵 ) 更多 | - | 2013-10-25 | |||
Placebo | |||||||
临床2期 | 547 | 遞憲簾鑰艱顧襯築鏇廠(遞鹽衊醖窪襯衊選齋遞) = 鬱憲積齋夢鹽鹹簾膚顧 淵廠衊鹹範選範獵衊築 (觸簾構獵壓製餘蓋淵齋, -35.0%) | 积极 | 2013-06-12 | |||
Placebo | 遞憲簾鑰艱顧襯築鏇廠(遞鹽衊醖窪襯衊選齋遞) = 築齋餘鹽廠衊鹽鏇齋範 淵廠衊鹹範選範獵衊築 (觸簾構獵壓製餘蓋淵齋, -5.1%) |






